Boston Biotech Adecto Pharmaceuticals Has Ceased Operations

The cancer research firm closed after failing to secure the funding needed to continue developing its lead therapy.

Updated on Oct. 2, 2026 in Healthcare

Isometric editorial illustration of a sterile glass laboratory centrifuge, representing the end of a biotech research firm's operations. — Boston-based Adecto Pharmaceuticals has officially ceased operations after failing to secure necessary funding to continue its cancer research program. AI Illustration. Upload story photo >

Live Poll

Is now a difficult time for early-stage medical research startups to secure funding?

Adecto Pharmaceuticals, a Boston-based biotech focused on ADAM8-positive cancers, has officially ceased operations. The company shut down after a 12-year run when it could not secure additional financial runway.

Why it matters

The closure highlights a challenging funding environment for early-stage biotechs, where investors are increasingly hesitant to support new therapeutic targets lacking clinical data. Adecto had relied heavily on National Cancer Institute grants to sustain its operations.

The firm operated for 12 years and utilized multimillion-dollar grants from the National Cancer Institute. It remains unclear how the company will transfer its intellectual property, including a provisional patent filed in August 2026.

The players

Adecto Pharmaceuticals

This Boston-based biotechnology company focused on developing novel therapies for ADAM8-positive cancers.

Nora Mineva

She served as the chief executive officer of Adecto Pharmaceuticals starting in 2023.

National Cancer Institute

This federal agency is the primary government body responsible for cancer research and provided grant funding to the company.

Tufts University

This private research university in Medford and Somerville is the academic institution where the company founders originated.

The details

Founded by researchers from Tufts University, Adecto specialized in therapies targeting ADAM8-positive cancers. The leadership team is now exploring alternative pathways to ensure the continued development of its specialized research.

Adecto Pharmaceuticals launched in 2014.
Nora Mineva took over as CEO in 2023.
The company filed a provisional patent for ADAM8 in August 2026.
Adecto Pharmaceuticals officially closed in October 2026.

Market Landscape

The firm's reliance on National Cancer Institute grant funding mechanisms reflects the broader struggle for biotech startups to transition from early research to commercial stability. This closure underscores how difficult it is for companies without private clinical-stage funding to maintain momentum in the current economic environment.

The shutdown of the company halts the development of specific therapies that had not yet reached clinical trial stages. Local biotech stakeholders should monitor how the firm's assets are liquidated or acquired, as this will determine the future accessibility of these potential cancer treatments.

The takeaway

Early-stage biotech firms often struggle to bridge the gap between academic research and commercial viability in a risk-averse investment climate. Developers must focus on securing diversified funding streams early to avoid being forced into closure before their therapies reach clinical trials.